Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs iShares MSCI Taiwan ETF (EWT) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade
iShares MSCI Taiwan ETFTrade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs iShares MSCI Taiwan ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while iShares MSCI Taiwan ETF trades at $106.43. The key difference: iShares MSCI Taiwan ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.

ALNYEWT
Market Cap
$29.60B
Sector
HealthBroad Market / Factor
52-Week High
$491.22$111.53
52-Week Low
$205.48$58.05
Enterprise Value
$27.56B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alnylam Pharmaceuticals, Inc.

ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.

Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.

iShares MSCI Taiwan ETF

EWT (iShares MSCI Taiwan ETF) trades at $106.19, up 3.92% with strong bullish momentum from moving averages. The ETF benefits from Taiwan's AI-driven semiconductor exposure, particularly through TSMC's 22.5% weighting. Recent news highlights continued capital flows into Taiwan's tech sector despite regional volatility, with MediaTek and ASE Technology announcing significant AI-related investments.

Outlook remains positive given Taiwan's leadership in semiconductor manufacturing and AI supply chain dominance. Key risks include geopolitical tensions with China and potential rotation away from AI-heavy markets. Institutional sentiment appears constructive with selective foreign inflows supporting the ETF's premium valuation.

Returns comparison

Trailing returns across standard periods

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Read more on ALNY

About iShares MSCI Taiwan ETF

EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.

Read more on EWT